Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after ...

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed ...

In an interview with Targeted OncologyTM, Massimo Cristofanilli, MD, medical oncologist at the Breast Center at Weill Cornell ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Larotrectinib is a highly selective and central nervous system-active TRK inhibitor, approved for adult and pediatric ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.